How Reliable Are Staging and Grading for Periodontitis? What They Mean for Your Treatment

What does "staging: severity and complexity" mean for me as a patient?

One of the most common questions patients have about this topic concerns staging: severity and complexity. The answer is not as simple as you might hope — but research now gives clear guidance.

The staging system divides gum disease (periodontal disease) into four stages (I–IV) based on clinical and X-ray findings. The main criteria are the amount of gum recession measured clinically (CAL), bone loss visible on X-rays, and teeth lost due to gum disease. Additional complexity factors — including pocket depth, bone loss in tooth-supporting areas with multiple roots, and tooth movement — determine whether a case is classified into a higher stage (Tonetti et al. 2018). The BSP guideline (West et al. 2021) adopts this system fully and emphasizes that the stage classification determines how intensive your treatment needs to be: Stages I and II usually require non-surgical treatment, while Stages III and IV often need surgical procedures and coordinated care involving multiple specialists.

The European S3 guideline is based on 15 systematic reviews conducted as part of the EFP workshop (Sanz et al. 2020). These reviews addressed specific research questions about each treatment level and enabled evidence-based recommendations. The BSP version adapted by West et al. (2021) used the GRADE-ADOLOPMENT method to tailor the European recommendations for the British healthcare system, involving 75 delegates from 17 stakeholder organizations. This careful approach gives the recommendations a high level of transparency and reliability.

Hashim et al. (2025) examined in a systematic review specifically orthodontic treatment in patients with Stage III and IV gum disease (periodontitis). Their analysis of 17 studies shows that integrating orthodontic measures into periodontal therapy can achieve clinically relevant improvements: average gains in clinical attachment level of 4.35–5.96 mm, reductions in probing depth of 3.1–6.3 mm, and radiological bone regeneration with an average vertical bone fill gain of 4.89 mm. These results remained stable at follow-up periods of up to ten years.

The Cochrane review by Liu et al. (2019) examined the link between periodontal therapy and cardiovascular prevention in people with gum disease. Although this study primarily focused on cardiovascular endpoints, it is relevant to the staging system because it shows that severe gum disease (periodontitis) (which corresponds to the higher stages) is associated with systemic health risks. However, the scientific evidence was very low (GRADE: very low certainty) and was based on only two randomized controlled trials with high risk of bias, so no reliable conclusions about the cardiovascular effectiveness of periodontal therapy were possible.

Methodologically, it should be noted that the included studies varied considerably in study design, follow-up period, and population selection. This variability limits the comparability of the results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different types of studies.

For applicability to the German-speaking healthcare context, it is additionally important that a substantial portion of the scientific evidence comes from English-speaking or Scandinavian healthcare systems. Differences in reimbursement structures, treatment culture, and patient access can influence effect sizes without invalidating the basic findings.

For clinical decision-making, the staging system is a practical tool for treatment planning. Stages I and II characterize early to moderate gum disease (periodontitis), in which non-surgical therapy (subgingival instrumentation) is the focus. Stages III and IV mark advanced disease, in which surgical, regenerative, and often interdisciplinary treatment concepts are necessary. The guideline by West et al. (2021) structures these decisions in four treatment levels, which build on one another and are only escalated if response is insufficient.

In daily practice, the main difficulty lies in distinguishing between neighboring stages — particularly between Stage II and III. Here, complexity factors such as vertical bone defects, furcation involvement Grade II/III, or probing depths greater than 6 mm are decisive. Since these factors are not always clearly present or may vary, there is a diagnostic gray area that requires clinical judgment.

In everyday practice, this means: The scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be included in the decision.

What does this mean for you? The classification must be understood as a clinical tool, not as an exact measuring instrument.

As a patient, it is important for you to know: No examination method is perfect. Research shows under what conditions a method is most reliable and when you should ask for a second opinion.

Science has examined this topic intensively in recent years. For this article, more than 8 scientific papers were evaluated. It is important to understand: Not every study has the same level of evidence. Large, well-controlled studies provide more reliable results than small observational studies. The overall picture from these different studies is what we present to you here.

What does "Grading: Progression Risk" mean for me as a patient?

When it comes to grading: progression risk, the research situation is clearer than many think. Here you will find out what the current studies really show.

The grading system supplements staging with a prognostic dimension. It differentiates three grades (A, B, C) that estimate the progression risk of gum disease (periodontitis). The primary criterion is radiological bone loss in relation to the patient's age; secondary modifiers are smoking and diabetes mellitus (Tonetti et al. 2018). Grade A corresponds to slow progression, Grade B to moderate progression, and Grade C to rapid progression. The BSP guideline (West et al. 2021) integrates grading into treatment planning by recommending more intensive and closer monitoring concepts for Grade C.

Hashim et al. (2025) report that patients with Stage IV, Grade C gum disease (periodontitis) showed the strongest improvements with combined gum-related and orthodontic therapy, especially when orthodontic intervention began early after regenerative therapy. This suggests that grading is not only prognostic but also relevant for choosing the timing of therapy. However, these results are based on a limited number of heterogeneous studies, and prospective comparative studies stratifying outcomes by grade are still lacking.

The Cochrane review by Liu et al. (2019) indirectly illustrates the relevance of grading for systemic comorbidities. The included primary prevention study examined people with gum disease and metabolic syndrome — a patient group that would typically be assigned Grade B or C under the grading system, since diabetes and obesity are considered risk modifiers. However, the scientific evidence was insufficient to draw causal conclusions.

A key problem with grading concerns the radiological determination of progression rate. It requires longitudinal X-rays over several years, which are often not available in practice. Without comparison images, the progression rate can only be estimated indirectly through the ratio of bone loss to age, which can lead to systematic misjudgments in older patients with cumulative bone loss. The guideline by West et al. (2021) does not explicitly address this problem, and the included reviews also offer no solution to this diagnostic dilemma.

Methodologically, it should be noted that the included studies varied considerably in study design, follow-up period, and population selection. This variability limits the comparability of the results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different types of studies.

For applicability to the German-speaking healthcare context, it is additionally important that a substantial portion of the scientific evidence comes from English-speaking or Scandinavian healthcare systems. Differences in reimbursement structures, treatment culture, and patient access can influence effect sizes without invalidating the basic findings.

Grading influences clinical decisions on two levels: First, it determines therapy intensity — Grade C patients receive closer follow-up intervals and more frequent adjunctive systemic antibiotics. Second, it modulates prognostic assessment, for example when deciding whether a severely compromised tooth should be retained or extracted.

In everyday practice, the most common challenge is distinguishing between Grade A and B in patients without clear risk factors and without previous X-ray records. In these cases, the standard Grade B is assigned, which can mean that a significant number of patients receive an unclear medium risk assessment. This weakens the system's ability to discriminate between different risk levels.

In daily practice, this means: The scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as overall health, compliance, individual risk profiles, and treatment preferences must be considered in the decision.

What does this mean for you? Uncertainties in grading must be communicated clearly.

As a patient, it's important to know: No examination method is perfect. Research shows under what conditions a method is most reliable and when you should ask for a second opinion.

How do scientists reach these conclusions? They don't just evaluate a single study, but look at many research projects at the same time. This allows them to determine whether a result was coincidental or whether it is confirmed repeatedly. In this case, the findings are based on 8 scientific papers from different countries and research groups.

What does "impact on treatment decisions" mean for me as a patient?

One thing that often causes uncertainty is the impact on treatment decisions. But science has made important progress in recent years.

The BSP guideline (West et al. 2021) defines a four-step treatment pathway that is directly linked to the staging system. Step 1 includes behavior change, risk factor control, and professional mechanical plaque removal. Step 2 includes below-the-gum-line cleaning, which is recommended for all stages, and may be enhanced with additional measures. Step 3 includes surgical interventions (access flap, resection procedures, regenerative surgery), which are primarily indicated for Stage III and IV with remaining deep pockets after Step 2. Step 4 is lifelong supportive gum disease therapy.

The 15 systematic reviews underlying the EFP guideline provide the scientific basis for each treatment step. For below-the-gum-line cleaning (Step 2), scientific evidence consistently shows clinically relevant improvements in pocket depth and attachment level (Suvan et al. 2020). For additional systemic antibiotics in Step 2, Teughels et al. (2020) found a statistically significant but clinically moderate additional benefit, with the guideline limiting their use to young patients with Grade C and generalized Stage III to minimize resistance problems.

Hashim et al. (2025) expand the view to interdisciplinary treatment approaches and show that orthodontic measures for Stage III and IV after successful gum disease pretreatment and regenerative therapy can make clinical sense. The authors emphasize that reduced orthodontic forces and close interdisciplinary coordination are prerequisites for safe results. Long-term follow-ups of up to ten years documented stable results, although study quality varied and no randomized controlled trials were available.

For overall health effects of gum disease therapy, the Cochrane review by Liu et al. (2019) provides no reliable scientific evidence. Based on only two randomized controlled trials with high risk of bias and very low quality of evidence (GRADE), neither a benefit nor harm of gum disease therapy regarding cardiovascular outcomes could be established. This underscores that the primary reason for gum disease treatment lies in gum disease outcomes, and while overall health benefits are biologically plausible, they are not proven by intervention studies.

The guideline explicitly emphasizes that treatment planning depends not only on the stage, but also on how well a patient responds to the previous step. Automatically assigning a treatment based on stage alone is not intended; instead, the condition is reassessed after each step and treatment is adjusted if the response is insufficient. This step-care model reflects clinical reality better than rigid algorithms.

Methodologically, it should be noted that the included studies vary considerably in study design, follow-up period, and population selection. This variation limits the comparability of results and explains why combined effect estimates must be interpreted with caution. Nevertheless, the direction of effect is consistent across different study types.

For application to German-speaking healthcare settings, it is also relevant that a significant portion of scientific evidence comes from English-speaking or Scandinavian healthcare systems. Differences in payment structures, treatment culture, and patient access can affect effect sizes without invalidating the main conclusions.

The stepwise treatment pathway provides dentists with a clear decision structure. The most important clinical implication is that surgical measures should only be performed after completion and reassessment of non-surgical therapy — unless specific complexity factors (such as deep vertical bone defects or Grade III furcation involvement) require earlier surgical intervention.

For interdisciplinary collaboration, scientific evidence from Hashim et al. (2025) shows that orthodontic treatment in advanced gum disease (periodontitis) is not contraindicated, but requires strict conditions: stable gum disease after pretreatment, reduced forces, and frequent gum disease monitoring during the orthodontic phase.

In daily practice, this means: Scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as overall health, compliance, individual risk profiles, and treatment preferences must be considered in the decision.

What does this mean for you? The article must put the benefits of classification into practical perspective.

As a patient, it's important to know: No examination method is perfect. Research shows under what conditions a method is most reliable and when you should ask for a second opinion.

What makes these results reliable? In medical research, the following applies: the more independent studies that reach the same conclusion, the more certain the statement. The type of study and number of participants also play an important role. Large controlled studies with many participants provide more reliable results than small surveys.